Recruitment of HDACs to the CDH1 promoter is regulated by the transcription factor ZEB1, and inhibition of HDACs may be a promising antitumour therapy for pancreatic cancer [145]. This evidence concerns the gene CDH1 and familial pancreatic carcinoma.